CapsoVision vs Nexgel
CapsoVision reported revenue of $14 million in fiscal 2025, 1.2 times Nexgel's $11 million in fiscal 2025. CapsoVision's revenue grew 15.3% in its latest year, and Nexgel's grew 31.5%. CapsoVision had an operating margin of -188.2%, against -29.4% at Nexgel. Free cash flow was −$23 million at CapsoVision and −$1 million at Nexgel.
Side by side
| CapsoVision | Nexgel | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $14M | $11M |
| Revenue growth | 15.3% | 31.5% |
| Revenue growth a year, last 5 years | — | 74.7% |
| Gross margin | 52.9% | 39.5% |
| Operating margin | −188.2% | −29.4% |
| Net margin | −186.8% | −26.3% |
| Free cash flow | −$23M | −$1M |
| Free cash flow margin | −169.3% | −12.1% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1,115.6% | 20.6% |
| Last close | $6.31 | $3.35 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $16.0 million, sold $0 | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CapsoVisionNexgel
Operating margin
Percent of revenue
CapsoVisionNexgel
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CapsoVisionNexgel
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CapsoVision and Nexgel pages.